12,372 trials
Diabetic Macular Edema
Primary: Change From Baseline at Week 52 in Best-corrected Visual Acuity (BCVA) for the Study Eye. — 10.6; 11.9 Scores on a scale — p=0.013
Crohn's Disease
Primary: Percentage of Participants With Combined Remission at Week 24 — 46.32; 48.76 percentage of participants — p==0.571
Ulcerative Colitis
Primary: The Level of Immunoglobulin (Ig) A — 270.42; 208.63 mg/dL
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 52; 12 Participants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination — 26.3; 29.7; 32.5; 13.2 Percentage of participants
Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — NA; NA months — p=0.0518
Obstructive Hypertrophic Cardiomyopathy
Primary: Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient — -51.05; 19.23 mmHg
Agitation Associated With Dementia of the Alzheimer's Type
Primary: The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 90.2; 90.3 Percentage of percipitante
Parenteral Nutrition Associated Liver Disease · Short Bowel Syndrome · Gastrointestinal Disease
Primary: Reversal of Cholestasis, Defined as a Direct Bilirubin to <= 2.0 mg/dL. — 11.7; 6.4 Weeks — p==0.001
Presbyopia
Primary: Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity — 49.4; 35.0; 22.7 Percentage of participants — p=<.001
Pneumonia, Pneumococcal
Primary: Number of Participants With Solicited Injection-site Adverse Events (AEs) — 317; 314 Participants
Follicular Lymphoma · Small Lymphocytic Lymphoma · Marginal Zone Lymphoma
Primary: Event Free Survival — 47.7; 49.5 Percentage of Participants — p=0.26
Platelet Dysfunction Due to Drugs
Primary: P2Y12 Reaction Units — 187.35 P2Y12 Reaction Units
Spinal Muscular Atrophy
Primary: Six Minute Walk Test (6MWT) With Kinematic Evaluation of Gait (Short Term) — 293.05; 299.50 meters
Hiv
Primary: Tenofovir Diphosphate (TFV-DP) Levels in Plasma and Intracellular Levels in Pregnant Women on Daily PrEP — 580; 71 TFV-DP PBMC (fmol/10^6cells)